Automate Your Wheel Strategy on IRMD
With Tiblio's Option Bot, you can configure your own wheel strategy including IRMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IRMD
- Rev/Share 6.1058
- Book/Share 7.0825
- PB 9.8581
- Debt/Equity 0.0007
- CurrentRatio 8.8673
- ROIC 0.2024
- MktCap 888110400.0
- FreeCF/Share 1.1009
- PFCF 63.4457
- PE 42.9751
- Debt/Assets 0.0006
- DivYield 0.0095
- ROE 0.243
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
IRadimed: Continued Value Unlock With Extensive Reinvestment Runway
Published: August 21, 2025 by: Seeking Alpha
Sentiment: Positive
IRadimed Corporation demonstrates exceptional economic characteristics, with high NOPAT margins, robust free cash flow, and consistent value creation for shareholders. Management has effectively reinvested capital, generating over $18 in market value for every $1 invested since FY'22, and consistently exceeding a 12% ROIC hurdle rate. Despite modest sales growth, IRMD's profitability and cash conversion remain strong, with a persistent ability to redeploy earnings at attractive returns.
Read More
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2025 Earnings Conference Call August 1, 2025 11:00 AM ET Company Participants John F. Glenn - CFO & Corporate Secretary Roger E.
Read More
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
Read More
IRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Read More
IRadimed (IRMD) Lags Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago.
Read More
CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025". The corrected release follows:
Read More
IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
Read More
IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space
Published: April 08, 2025 by: Seeking Alpha
Sentiment: Positive
IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump and patient monitoring system face limited competition, ensuring a strong market position. Financials show robust performance with a 21% increase in US sales, but international sales dipped possibly due to cheaper alternatives in Asian markets.
Read More
About IRadimed Corporation (IRMD)
- IPO Date 2014-07-16
- Website https://www.iradimed.com
- Industry Medical - Devices
- CEO Roger E. Susi
- Employees 160